Peter Nash

Professor

Griffith University

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Immunology Immunology professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (4)

Gerd-Rüdiger Burmester

Senior Professor

Charité - Universitätsmedizin Berlin

GERMANY

View details

Francisco J. Blanco-García

Universidade da Coruña

SPAIN

View details

Vinod Chandran

University Health Network

CANADA

View details

Ennio Lubrano

University of Molise

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Peter Nash

Research Interests

Explore related searches

Contact this professor

Articles (10)

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

Impact of COVID-19 on Patients With Psoriasis or Psoriatic Arthritis

Response to: ‘Correspondence on ‘Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement’’ by Bandayet al

Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial

JAK inhibitors: new indication and emerging safety data in 2022

Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease Mechanisms

Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis

Janus Kinase Inhibitors: Safety in Patients With Psoriatic Arthritis

Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials

Collaborators (4)

Gerd-Rüdiger Burmester

Francisco J. Blanco-García

Vinod Chandran

Ennio Lubrano

Make your next move.